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The malaria testing and treatment
landscape in Kenya: results from a nationally
representative survey among the public
and private sector in 2016
ACTwatch Group1*, Anne Musuva2, Waqo Ejersa3, Rebecca Kiptui3, Dorothy Memusi3 and Edward Abwao4

Abstract
Background: Since 2004, Kenya’s national malaria treatment guidelines have stipulated artemisinin-based combination therapy (ACT) as first-line treatment for uncomplicated malaria, and since 2014, confirmatory diagnosis of malaria
in all cases before treatment has been recommended. A number of strategies to support national guidelines have
been implemented in the public and private sectors in recent years. A nationally-representative malaria outlet survey,
implemented across four epidemiological zones, was conducted between June and August 2016 to provide practical
evidence to inform strategies and policies in Kenya towards achieving national malaria control goals.
Results: A total of 17,852 outlets were screened and 2271 outlets were eligible and interviewed. 78.3% of all
screened public health facilities stocked both malaria diagnostic testing and quality-assured ACT (QAACT). Sulfadoxine–pyrimethamine (SP) for intermittent preventive treatment in pregnancy was available in 70% of public health
facilities in endemic areas where it is recommended for treatment. SP was rarely found in the public sector outside of
the endemic areas (< 0.5%). The anti-malaria stocking private sector had lower levels of QAACT (46.7%) and malaria
blood testing (20.8%) availability but accounted for majority of anti-malarial distribution (70.6% of the national market
share). More than 40% of anti-malarials were distributed by unregistered pharmacies (37.3%) and general retailers
(7.1%). QAACT accounted for 58.2% of the total anti-malarial market share, while market share for non-QAACT was
15.8% and for SP, 24.8%. In endemic areas, 74.9% of anti-malarials distributed were QAACT. Elsewhere, QAACT market
share was 49.4% in the endemic-prone areas, 33.2% in seasonal-transmission areas and 37.9% in low-risk areas.
Conclusion: Although public sector availability of QAACT and malaria diagnosis is relatively high, there is a gap in
availability of both testing and treatment that must be addressed. The private sector in Kenya, where the majority of
anti-malarials are distributed, is also critical for achieving universal coverage with appropriate malaria case management. There is need for a renewed commitment and effective strategies to ensure access to affordable QAACT and
confirmatory testing in the private sector, and should consider how to address malaria case management among
informal providers responsible for a substantial proportion of the anti-malarial market share.
Keywords: Malaria control case management, Anti-malarial, ACT, Private sector, Public sector, Malaria diagnosis, Kenya
Background
Malaria is the leading cause of morbidity and mortality in Kenya, with over 70% of the population at risk of
*Correspondence: mcsd@psi.org
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infection [1]. In 2013, there were over 2.3 million confirmed cases of malaria, accounting for more than 20% of
outpatient visits, 19% of hospital admissions and 3–5% of
hospital deaths [2]. However, there have been important
reductions in malaria prevalence in recent years. Between
2010 and 2015, national data reveal malaria prevalence
in children aged 6 months to 14 years fell from 11 to 8%
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respectively. Furthermore, from 2011 to 2015 the suspected outpatient malaria cases, as a proportion of the
outpatient department cases, declined from over 35 to
15% [3]. However, regional variations are apparent, and
analysis has shown a trend of increased prevalence of
Plasmodium falciparum in the coastal-endemic area over
the same period [3, 4].
Given the variability in malaria transmission throughout the country, the Kenya National Malaria Control
Programme has defined epidemiological zones based on
malaria risk and burden [5]. These malaria epidemiological zones are largely defined by altitude, rainfall patterns
and temperature. They include: endemic areas around
Lake Victoria in western Kenya and in the coastal region;
highland epidemic-prone areas of western Kenya and the
Rift Valley region; seasonal-transmission areas, which are
the arid and semi-arid areas of the northern and south
eastern parts of the country; and low-risk areas in the
central highlands of Kenya including Nairobi [5]. These
epidemiological zones are used to guide the implementation of malaria control interventions, including intermittent preventive treatment in pregnancy (IPTp) and
community case management, which are both focused in
endemic areas.
Following a recognition that sulfadoxine–pyrimethamine (SP) was failing, in 2004 the National Malaria Control Programme adopted artemether–lumefantrine (AL)
as the first-line treatment for uncomplicated malaria,
with the change being widely implemented from 2006
onwards [6]. The national malaria control guidelines, recommend dihydroartemisinin-piperaquine as the secondline treatment for uncomplicated malaria in Kenya. The
treatment recommendation for severe malaria is parenteral artesunate, while treatment with parenteral quinine is permitted in absence of artesunate. Patients with
severe malaria should be referred to higher levels of care.
SP is recommended for IPTp only in the malaria endemic
zones. The 2014 Kenya national malaria control guidelines recommend confirmatory diagnosis of malaria in all
age-groups of patients in all epidemiological settings [7].
This was a departure from the previous guidelines that
recommended presumptive treatment.

National malaria control strategies
and interventions for case management
Several strategies have been implemented to ensure
access to quality case management services and commodities. Between 2010 and 2013, Kenya and other six
countries (Ghana, Madagascar, Niger, Nigeria, Tanzania [including Zanzibar] and Uganda) participated in
the Affordable Medicines Facility for malaria (AMFm).
The AMFm provided quality-assured ACT (QAACT)
to wholesalers at a heavily-subsidized cost with the
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objective of increasing access to affordable ACT in
both the public and private sector [8]. The packaging of
AMFm-subsidized QAACT was marked with a distinctive green leaf logo for easy identification. By the end
of 2011, approximately 14.35 million co-paid QAACT
treatments were delivered to Kenya’s public sector and
14.1 million to the private sector [9]. The AMFm independent evaluation reported significant improvements in
availability, price, and relative market share of QAACT in
Kenya, and especially in the private sector [8, 10].
Building on the successes of the AMFm, the Global
Fund introduced a new funding model, known as the
co-payment mechanism (CPM), to support private sector access to QAACT medicines. The CPM focused
exclusively on the private sector supply of QAACT given
that the independent evaluation showed that the AMFm
had greater impact on the supply of QAACT in the private than compared to the public sector [10]. However,
the public sector continued to receive subsidized ACT
through an alternative Global Fund mechanism. During the CPM, QAACTs in this sector were not marked
with the green leaf logo. While substantial resources
were provided by donor communities for procurement
of subsidized QAACT in Kenya for the period between
2013 and 2015, resources were not at their peak as during the AMFm period. In 2015, only 6.85 million treatments were delivered to the private sector through the
CPM. The ACT subsidy was also decreased to wholesalers from 90 to 70% for all pack sizes [9], lending to a recommended retail price of $1.00 to the consumer, for both
children and adults. Finally, while several mass communication activities were implemented to increase demand
and consumer awareness of QAACT, these were discontinued in mid-2015 [9].
In addition to the AMFm and CPM, other strategies have been implemented to increase availability and
demand for rapid diagnostic tests (RDTs) [5, 11]. In the
private sector, this was supported by changing national
policy to allow point-of-service testing beyond private
hospitals and large private for-profit health facilities to
registered pharmacies. In the public sector, RDTs were
permitted and supplied to lower-level facilities, including
community health workers (CHW) operating in malaria
endemic areas.
Data on the anti-malarial and malaria diagnostic
markets in Kenya provide an important benchmark
to measure the extent to which malaria case management services are available and are aligned with national
malaria control guidelines. The ACTwatch project, a
multi-country research project that was launched in
2008, provides timely, relevant and high quality evidence for this purpose [12]. The objective of this paper
is to provide practical evidence to inform strategies and
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policies in Kenya towards achieving national malaria
control goals, by describing the total market for malaria
medicines and diagnostics at national level. This paper
presents data from the recently conducted outlet survey
in 2016.

Methods
Design

A nationally-representative, cross-sectional quantitative
survey was conducted among outlets with potential to
stock anti-malarials or malaria diagnosis. All potential
public and private sector outlets were included in the
survey. The public sector included all tiers of the health
care system (hospitals, health centers, dispensaries, clinics and CHWs) owned by government or affiliated with
the not-for profit organizations such as non-governmental and faith-based institutions. Outlets surveyed in the
private sector included, private for-profit health facilities
(hospitals, nursing homes/medical centers and clinics),
pharmacies and chemists (registered and unregistered)
and general retailers selling fast-moving consumer goods.
Table 1 provides an additional description of the outlet
types.
Sampling

The 2016 survey was stratified to deliver estimates for
each of the aforementioned malaria epidemiological zones in Kenya. Clusters were selected from the
four malaria epidemiological zones and defined as (1)
endemic areas, (2) epidemic-prone areas, (3) seasonaltransmission areas, and (4) low-risk areas. Considering
that updated and comprehensive lists of all potentially
eligible outlets were not routinely available at both
national and sub-national levels, a cluster sampling
approach with an outlet census was used to identify
outlets for inclusion. A cluster was defined as an administrative unit ideally with a population of 10,000–15,000
inhabitants and this corresponded with a “location”.
Using 2009 Kenya Population and Housing Census
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[13], a national sampling framework was constructed
and survey clusters or locations were selected using
the technique of probability proportional to population
size.
The survey was powered to detect a minimum of a
10-percentage point change in availability of QAACT
medicines within each strata at the 5% significance level
with 80% power. The number of study clusters was calculated for each strata based on the required number
of anti-malarial stocking outlets, assumptions about
the number of anti-malarial stocking outlets per cluster
and information from previous survey rounds including
anti-malarial and QAACT availability, outlet density per
cluster, and design effect. A total of 84 locations were
sampled, this included 17 endemic locations, 22 epidemic-prone locations, 28 seasonal-transmission locations, and 17 low-risk locations. Within each sampled
location, all outlets with the potential to provide antimalarials or diagnostic testing services to patients or clients were screened for eligibility. In all sampled locations,
the census boundary was extended to the higher administrative unit, the “division”, to allow for over sampling of
public health facilities that are relatively uncommon at
the location level but important outlet type in health service provision.
Training and fieldwork

Data were collected between 7th June and 17th August,
2016 by 14 data collection teams. All fieldworkers
attended a standardized training that consisted of classroom presentations, exercises and role plays as well as
a field exercise. Additional training was provided for
supervisors and quality-controllers that focused on field
monitoring, verification visits, and census procedures.
Data collection teams were provided with a list of sampled locations and official maps that illustrated their
administrative boundaries. In each sampled location,
fieldworkers conducted a systematic and full enumeration of all outlets.

Table 1 Outlet descriptions
Public health facilities

Tertiary referral hospital, secondary referral hospitals, primary referral hospitals, health centers and dispensaries.
There are over 3000 Ministry of Health public health facilities in Kenya

Community health worker

Community-based health workers, including community health volunteers

Private for-profit health facilities

Private hospitals, clinics, dispensaries, and diagnostic laboratories. There are over 3100 registered private for-profit
health facilities in Kenya

Registered pharmacies/chemists

Pharmacies are licensed and regulated by the Pharmacy and Poisons Board and include Pharmacist Premises. By
2014, there were over 3900 registered Pharmacies in Kenya

Unregistered pharmacies/chemists

Small businesses that are not registered with the Pharmacy and Poisons Board, but sell various classes of prescription and over-the-counter medicine at commercial prices

General retailers

Supermarkets, duka, kiosks, market stalls, and petrol stations
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Measures

Data were collected using a standardized ACTwatch
outlet survey questionnaire and key informant interviews. Using the outlet survey questionnaire, the primary
provider/owner of each potential outlet was invited to
participate in the study and screening questions were
administered to assess eligibility. Consenting providers
were asked to show the interviewer all anti-malarials and
malaria RDTs currently available. An anti-malarial audit
sheet was completed to capture information for each
unique anti-malarial product in the outlet, including formulation, brand name, active ingredients and strengths,
package size, manufacturer and country of manufacture.
Providers were asked to report the retail and wholesale
cost for each medicine, as well as the amount distributed to individual consumers in the last week. Similarly,
among the outlets found stocking malaria RDTs, an audit
was completed to record information such as brand
name, manufacturer, country of manufacturer, reported
retail selling price and number of tests conducted or sold
in the last 7 days for each of unique RDT product. Finally,
a provider module was administered to assess provider’s
knowledge and reported practices on malaria case-management policy recommendations. Outlet survey data
were captured using Android phones fitted with customized forms created using DroidDB (© SYWARE, Inc.,
Cambridge, MA, USA). Interviews were conducted in
local language using questionnaires that were translated
from English to Swahili language and back to English to
confirm translations.
Protection of human subjects

The outlet survey protocol received ethical approval from
Kenyatta National Hospital–University of Nairobi Ethics & Research Committee (Reference Number KNHERC/A/145). Provider interviews and product audits
were completed only after administration of a standard
informed consent form and provider consent to participate in the study. Standard measures were employed to
maintain respondent confidentiality and anonymity, such
as ensuring privacy during interviews, secure storage of
completed questionnaires, and preventing any sharing of
data between outlets. Providers had the option to end the
interview at any point during the study.
Data analysis

Data were analysed using Stata version 13.1 (StataCorp
College Station, Texas, USA). Standard indicators were
constructed according to definitions applied across the
ACTwatch project and have been described elsewhere
[12, 14]. Descriptive analysis was undertaken, all point
estimates and 95% confidence intervals were weighted
to provide national estimates and calculated using Stata
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survey setting procedures to account for the complex
clustered and stratified sampling strategy. The sampling
weights were calculated as the inverse of the probability
of cluster selection. Data were presented according to the
four strata as well as by outlet types.
Definitions

According to information on drug formulation, active
pharmaceutical ingredients and strengths, anti-malarials
were classified as non-artemisinin therapies, artemisinin
monotherapies and ACTs. ACT medicines were further
classified as either QAACT or non-quality-assured ACT
(non-QAACT). QAACT was defined as ACT medicines
that had World Health Organization prequalification status, ACT medicines in compliance with the Global Fund
quality assurance policy, or ACT medicines granted regulatory approval by the European Medicines Agency. ACT
medicines that did not meet requirements for QAACTs
were categorized as non-QAACTs.
Availability of any anti-malarial was calculated with all
screened outlets as the denominator. In the public sector, the availability of specific types of anti-malarials was
calculated using the denominator of all screened outlets
given that anti-malarials should be available at all public
health facilities and among CHWs. Availability of specific anti-malarial categories in the private sector was
calculated using the total number of private sector outlets stocking any anti-malarial as the denominator. Outlet
“readiness” for malaria case management was defined as
the extent to which an outlet had QAACT and malaria
testing available.
This paper also presents market share and price indicators among different classes of anti-malarials. The
measure of adult equivalent treatment dose (AETD) was
deployed to analyse market share and price to allow for
meaningful comparisons between anti-malarials with different treatment courses. The AETD was defined as the
amount of active ingredient required to treat an adult
weighing 60 kg according to World Health Organization treatment guidelines [15]. Provider reports on the
amount of the drug sold or distributed during the week
preceding the survey were used to calculate sales or distribution volume according to type of anti-malarial. All
dosage formulations were included in the sales or distribution volume calculation to provide a complete assessment of anti-malarial market share to the consumer or
patient. Volumes were therefore the number of AETDs
sold or distributed by a provider in the 7 days prior to the
survey. Additional public health facilities sampled as part
of over-sampling for these outlet types were not included
in market share calculations.
Price data were collected in Kenya Shillings and converted to United States Dollar based on official exchange
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rates for the data collection period. Anti-malarial price
indicators are expressed as median unit cost for one
AETD to allow for comparability between classes of antimalarials. Only tablet formulations are reported due to
the differences in unit costs for tablet and non-tablet formulations. The interquartile range (IQR) was calculated
to demonstrate price dispersion.
Provider perceptions regarding the most effective firstline treatment was assessed by administering questions
to the senior most provider at all anti-malarial-stocking
outlets. Providers were asked to describe what medicine they believed was the most effective treatment for
uncomplicated malaria in a child and in an adult.

Results
Sample size description

A total of 17,852 outlets were screened for availability
of anti-malarials and/or malaria blood testing services.
Of screened outlets, 2291 were stocking anti-malarials
or testing on the day of the survey or within the past
3 months, and 2271 were subsequently interviewed. A
total of 1917 eligible and interviewed outlets were stocking anti-malarials on the day of the survey, 293 reportedly stocked anti-malarial(s) within the past 3 months
while 61 were found stocking malaria diagnostics without anti-malarial products. A total of 6716 anti-malarial
medicines and 846 RDT products were audited (Additional file 1).
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areas (59.8%), endemic-prone areas (63.9%), seasonaltransmission areas (48.9%) and low-risk areas (16.0%).
Of all screened public health facilities, 86.4% had
capacity for malaria blood testing, more commonly
through RDTs (69.7%) compared to malaria microscopy
(44.2%) (Table 3). Malaria blooding testing was lowest
among public health facilities in endemic areas (79.9%).
Among all screened CHWs, availability of RDTs was
4.3% and was highest in the endemic areas (7.3%) and
endemic-prone areas (8.0%), compared to the seasonaltransmission areas and low-risk areas where availability
was less than 1%.

Table 2 Availability of anti-malarials in the public sector,
among all screened outlets
CHWb

% (95% CI)

% (95% CI)

Any anti-malarial
Total

91.8 (89.2, 93.8)

2.4 (0.9, 6.3)

Endemic

99.0 (95.8, 99.8)

4.2 (1.0, 15.6)

Endemic-prone

97.6 (91.9, 99.3)

3.5 (0.8, 14.9)

Low-risk

81.0 (72.2, 87.5)

0.0 (–)

Seasonal-transmission

91.5 (86.5, 94.7)

0.7 (0.2, 2.2)

QAACT

Public sector availability

Table 2 summarizes the availability of anti-malarials
and diagnostics among the screened public sector outlets on the day of survey. Availability of any anti-malarial medicine was 91.8 and 2.4% among CHW, and this
was highest in the endemic areas (99.0%) and lowest in
the low-risk areas (81.0%). Among the screened outlets, 87.1% of public health facilities had QAACT medicines available and this varied by epidemiological zone:
endemic areas (92.2%), endemic-prone areas (93.5%),
seasonal-transmission areas (87.5%) and low-risk areas
(77.0%). Public health facility availability of weight specific QA AL was variable: 66.4% for 6 tablet-pack QA
AL, 63.3% for 12 tablet-pack QA AL, 37.0% for 18 tabletpack QA AL and 72.7% for adult tablet-pack of QA AL
(Additional file 2). Availability of non-QAACT medicines
among all screened public health facilities was 12.3% and
highest in the low-risk areas (17.8%). Overall availability of SP among the screened public health facilities was
17.6%, but this varied by epidemiological zone, where
availability was 70.0% in endemic areas and less than 1%
across all other epidemiological zones. Of all screened
public health facilities, 46.0% stocked artesunate injection and this varied by epidemiological zone: endemic

Public Health Facilitya

Total

87.1 (83.0, 90.4)

2.4 (0.9, 6.3)

Endemic

92.2 (77.8, 97.6)

4.2 (1.0, 15.6)

Endemic-prone

93.5 (85.0, 97.3)

3.5 (0.8, 14.9)

Low-risk

77.0 (66.1, 85.2)

0.0 (–)

Seasonal-transmission

87.5 (80.1, 92.4)

0.7 (0.2, 2.2)

Non-QAACT
Total
Endemic
Endemic-prone

12.3 (7.9, 18.7)

0.1 (0.0, 0.3)

9.3 (3.4, 22.9)

0.1 (0.0, 0.7)

10.7 (5.1, 20.8)

0.1 (0.0, 1.2)

Low-risk

17.8 (7.2, 37.9)

0.0 (–)

Seasonal-transmission

10.8 (4.2, 25.2)

0.0 (–)

SP
Total

17.6 (13.7, 22.3)

0.0 (–)

Endemic

70.0 (56.4, 80.8)

0.0 (–)

Endemic-prone

0.4 (0.0, 3.2)

0.0 (–)

Low-risk

0.1 (0.0, 0.6)

0.0 (–)

Seasonal-transmission

0.0 (–)

0.0 (–)

Artesunate IV/IM
Total

46.0 (39.7, 52.3)

0.0 (–)

Endemic

59.8 (41.6, 75.7)

0.0 (–)

Endemic-prone

63.9 (50.9, 75.2)

0.0 (–)

Low-risk

16.0 (6.8, 33.4)

0.0 (–)

Seasonal-transmission

48.9 (39.3, 58.7)

0.0 (–)

a

Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonaltransmission, N = 217

b

Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonaltransmission, N = 505
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Table 3 Availability of malaria diagnostic testing in the
public sector, among all screened outlets

Table 4 Readiness for malaria case management in the
public sector, among all screened outlets

Public Health F
 acilitya

CHWb

Public Health Facilitya CHWb

% (95% CI)

% (95% CI)

% (95% CI)

Total

86.4 (82.4, 89.6)

4.3 (2.2, 8.2)

Total

78.3 (73.6, 82.4)

1.9 (0.7, 4.9)

Endemic

79.9 (68.8, 87.8)

7.3 (3.1, 16.2)

Endemic

75.6 (61.9, 85.5)

3.2 (0.8, 11.8)

Endemic-prone

89.9 (84.7, 93.4)

8.0 (2.2, 24.8)

Endemic-prone

84.6 (76.5, 90.3)

3.3 (0.7, 13.9)

Low-risk

88.4 (77.1, 94.5)

0.0 (–)

Low-risk

72.8 (61.6, 81.7)

0.0 (-)

Seasonal-transmission

87.6 (82.5, 91.4)

0.4 (0.1, 1.6)

Seasonal-transmission

81.4 (73.1, 87.5)

0.4 (0.1, 1.6)

Any diagnostic test

% (95% CI)

QAACT and malaria testing available

Microscopy

QAACT available but no malaria testing available

Total

44.2 (40.1, 48.4)

0.1 (0.0, 0.4)

Total

Endemic

48.3 (41.2, 55.5)

0.0 (–)

Endemic

Endemic-prone

47.0 (39.0, 55.2)

0.0 (–)

8.8 (6.2, 12.3)

0.5 (0.2, 1.7)

16.7 (9.2, 28.3)

1.0 (0.2, 4.7)

Endemic-prone

8.8 (5.6, 13.7)

0.3 (0.0, 2.3)

Low-risk

45.7 (36.3, 55.5)

0.0 (–)

Low-risk

4.2 (1.5, 11.7)

0.0 (-)

Seasonal-transmission

36.8 (28.4, 46.1)

0.2 (0.0, 1.6)

Seasonal-transmission

6.1 (3.4, 10.7)

0.3 (0.1, 1.8)

RDT

a

Total

69.7 (62.8, 75.9)

4.3 (2.2, 8.2)

Endemic

57.3 (40.7, 72.4)

7.3 (3.1, 16.2)

Endemic-prone

69.9 (60.3, 78.1)

8.0 (2.2, 24.8)

Low-risk

80.5 (65.7, 89.8)

0.0 (–)

Seasonal-transmission

70.5 (57.9, 80.6)

0.4 (0.1, 1.6)

a

Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonaltransmission, N = 217

b

Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonaltransmission, N = 505

Among all screened public health facilities, 78.3%
had both QAACT medicines and malaria blood testing available, and this varied by epidemiological zone:
endemic areas (75.6%), endemic-prone areas (84.6%),
seasonal-transmission areas (72.8%) and low-risk areas
(81.4%) (Table 4). Only 8.8% of public health facilities had
QAACT medicines available but no malaria blood testing, and this was highest in the endemic areas (16.7%).
Private sector availability

Among all screened private sector outlets, availability
of any anti-malarial varied by facility type: private-forprofit facilities (76.4%), registered pharmacies (93.3%),
un-registered pharmacies (87.2%), and general retailers
(2.4%) (Table 5). Among the anti-malarial stocking private sector outlets 46.7% had QAACT medicines, and
this was highest among registered pharmacies (73.2%)
and lowest among general retailers (9.9%). Private sector
availability of QAACT medicines also varied by epidemiological zone: endemic areas (66.7%), endemic-prone
areas (43.0%), seasonal-transmission areas (33.8%) and
low-risk areas (42.2%) (Additional file 3). Availability of
non-QAACT medicines was 37.9% in the private sector, and highest among anti-malarial stocking registered pharmacies (76.8%). Non-artemisinin therapy was

Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonaltransmission, N = 217

b

Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonaltransmission, N = 505

stocked by 69.6% of the private sector and this was most
commonly SP (57.6%). SP availability varied by outlet
type, from 25.6% of private-for-profit facilities to 85.2% of
general retailers.
The availability of diagnostic testing among antimalarial-stocking private sector outlets was 20.8% (12.4%
malaria microscopy and 12.4% RDT), and varied by outlet type: private for–profit facilities (66.9%), registered
pharmacies (22.4%), unregistered pharmacies (12.1%)
and general retailers (0.2%).
Anti‑malarial market share

Figure 1 illustrates the anti-malarial market share (the
amount of anti-malarials sold or distributed during the
week preceding the survey) across the public and private
sector, according to outlet type and by anti-malarial. In
total, 70.6% of anti-malarials were distributed through
the private sector. Most of the private sector distribution
was through unregistered pharmacies (37.3%) followed
by private for-profit health facilities (13.4%), registered
pharmacies (12.8%) and general retailers (7.1%). Antimalarial market share for the public sector was 29.4% and
nearly all treatments distributed were QAACT medicines
(25.6%). Within the private sector, 32.5% of the market
share was accounted for by QAACT medicines, followed
by non-QAACT medicines (15.0%) and non-artemisinin
therapy (27.2%), which was typically SP (22.1%).
The private-sector market share of all anti-malarials
varied across epidemiological zones (Fig. 2): endemic
areas (59.2%), endemic-prone areas (68.8%), seasonal-transmission areas (81.8%) and low-risk areas
(94.9%). QAACT medicines market share was highest
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Table 5 Availability of malaria commodities in the private sector
Private For-Profit Facility Registered pharmacy Unregistered pharmacy General retailer Total private sector
% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

N = 360

N = 145

N = 493

N = 14,204

N = 15,202

76.4

93.3

87.2

2.4

7.1

(70.4, 81.4)

(87.8, 96.5)

(82.8, 90.6)

(1.7, 3.5)

(6.4, 7.9)

N = 280

N = 134

N = 428

N = 244

N = 1086

59.3

73.2

64.3

9.9

46.7

(51.2, 67.0)

(65.6, 79.7)

(58.6, 69.7)

(5.1, 18.4)

(39.4, 54.1)

52.3

76.8

48.5

3.0

37.9

(44.6, 59.9)

(68.7, 83.3)

(41.4, 55.6)

(1.3, 6.8)

(31.5, 44.7)

25.6

49.9

55.2

85.2

57.6

(19.5, 32.9)

(38.9, 61.0)

(47.1, 63.0)

(75.1, 91.6)

(50.8, 64.0)

Any non-artemisinin
therapy

50.3

57.2

68.7

88.5

69.6

(42.8, 57.8)

(45.1, 68.4)

(60.6, 75.8)

(78.9, 94.1)

(63.2, 75.4)

Artesunate injection

10.1

1.7

1.2

0.0

2.9

(5.9, 16.8)

(0.5, 5.6)

(0.5, 2.6)

–

(1.7, 4.7)

N = 307

N = 138

N = 467

N = 310

N = 1222

66.9

22.4

12.1

0.2

20.8

(59.2, 73.8)

(16.4, 29.8)

(9.1, 16.0)

(0.0, 1.4)

(16.5, 25.8)

48.1

8.8

3.2

0.0

12.4

(39.1, 57.3)

(5.0, 15.1)

(2.0, 5.3)

–

(9.1, 16.7)

36.0

16.0

9.5

0.2

12.6

(30.2, 42.3)

(11.1, 22.5)

(7.0, 13.0)

(0.0, 1.4)

(10.0, 15.8)

Availability of anti-malarials among all screened
outlets
Any anti-malarial
Availability of anti-malarials
among anti-malarialstocking outlets
QAACT
Non-QAACT
SP

Availability of blood testing
among anti-malarialstocking outletsa
Any diagnostic test
Malaria microscopy
RDT

Among outlets stocking anti-malarials todays or within the past 3 months

Percentage of total market volume

100
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80
70
60
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40
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20
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0

Public

Private

Private-For-Profit
Facility

Registered
Pharmacy

Unregistered
Pharmacy

General Retailer

QAACT with green leaf

QAACT without green leaf

Non QAACT

SP

Other non-artemisinin therapy

Non-oral artemisinin monotherapy

Fig. 1 Anti-malarial market share, by outlet type and anti-malarial type
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Percentage of total market volume

in endemic areas where (74.9% of anti-malarials distributed were QAACT), and lower in other zones:
endemic-prone areas (49.4%), seasonal-transmission
areas (32.2%) and low-risk areas (37.9%). Market share
for non-QAACT medicines was lowest in endemic
areas (9.7%) and highest in low-risk areas (24.8%). SP
market share was 14.2% in endemic areas, 27.5% in
endemic-prone areas, 45.7% in seasonal-transmission
areas and 33.9% in low-risk areas. SP was exclusively
distributed by the private sector in endemic-prone and
low-risk areas, and mostly by the private sector in seasonal-transmission areas (0.3% of the public sector and
45.4% of the private sector).

100
90
80
70
60
50
40
30
20
10
0

Public

Private

Endemic

Public

Malaria blood testing market share

Figure 3 shows that 66.9% of malaria blood testing was
performed in the public sector and within the sector the
market share of malaria microscopy (35.6%) and RDTs
(31.3%) was comparable. A third (33.1%) of blood testing market share was delivered through private sector outlets and testing was more commonly performed
through malaria microscopy (21.6%) than RDTs (11.5%).
Notably, majority of the private sector malaria tests were
delivered primarily by private-for-profit health facilities (28.5%) and was rare among registered pharmacies
(2.2%), unregistered pharmacies (2.4%) and general
retailers (0%).

Private

Public

Endemic-prone

QAACT with green leaf
SP
Non-oral artemisinin monotherapy

Private

Low-risk

QAACT without green leaf
Other non-artemisinin therapy

Public

Private

Seasonal-transmission
Non QAACT
Oral artemisinin monotherapy

Fig. 2 Anti-malarial market share, by epidemiological zones

Percentage of total market volume
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Fig. 3 Malaria testing market share, by outlet type and type of test
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Private sector price for malaria treatments and blood
testing

Table 6 summarizes the private sector median price for
anti-malarials and blood testing. The median retail price
for one QAACT AETD was $1.31 (IQR: 1.00–1.51). NonQAACT AETD was $3.52 (IQR: 1.51–5.02). The median
price for a SP AETD was $0.45 (IQR: 0.30–0.50) (Table 6).
In regard to the cost of malaria blood testing, an adult
patient was required to pay a median cost $1.00 to receive
a malaria test using microscopy (IQR: 0.50–1.51) or RDT
(IQR: 1.00–1.00). Similarly, the price of testing for children, either with microscopy or RDT, was $1.00 [microscopy (IQR: 0.50–100) or RDT (IQR: 0.50–100)].
Provider perceptions of the most effective treatment
for uncomplicated malaria

Figure 4 illustrates the extent to which providers perceived ACT as the most effective treatment for uncomplicated malaria in an adult. Nearly all providers (96.3%)
in the public sector perceived ACT as the most effective

Table 6 Median private sector price
N

Median

Interquartile range

Median price of a tablet AETD
QAACT

741

$1.31

1.00–1.51

Non-QAACT

845

$3.52

1.51–5.02

SP

768

$0.45

0.30–0.50

Median price of one test
Malaria microscopy for an adult

204

$1.00

0.50–1.51

Malaria microscopy for a child

203

$1.00

0.50–100

Malaria RDT for an adult

179

$1.00

1.00–1.00

Malaria RDT for a child

178

$1.00

0.50–1.00

treatment for uncomplicated malaria for adults. In the
private sector, 64.1% perceived ACT to be the most effective, 16.4% perceived SP as the most effective, 9.2% cited
another anti-malarial, and 10.2% did not know. General
retailers and unregistered pharmacy providers were the
most common outlet types to cite an anti-malarial other
than an ACT or to report that they did not know what
was the most effective treatment for malaria in an adult
(81.1 and 14.8%, respectively). With regards to perceptions of the most effective anti-malarial for a child, a similar pattern was observed: 95.3% public sector cited an
ACT, versus only 61.2% of private providers (Additional
file 4).

Discussion
This study provided a complete picture of the malaria
testing and treatment landscape across public and private
sectors in Kenya in 2016. Findings suggest that public
sector readiness to test and appropriately treat malaria
in Kenya is relatively high, but there is gap in availability
of both testing and treatment that must be addressed in
order to achieve universal coverage. In the private sector,
where the majority of anti-malarials are distributed, the
extent to which providers have malaria testing and appropriate anti-malarial medicines available is sub-optimal.
These findings in combination with results from previous
survey rounds, and current evidence from the different
epidemiological zones, point to the progress which has
been achieved as well as recommendations for improving
malaria case management in Kenya.
Public sector readiness to test and treat for malaria

Previous ACTwatch studies have demonstrated high availability of QAACTs and malaria blood testing since 2010
and 2014 respectively [16]. Nonetheless in 2016, one in

Percentage of providers
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Fig. 4 Provider perceptions on the most effective treatment for uncomplicated malaria in an adult
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five public health facilities did not have both QAACT and
malaria blood testing available, pointing to the need to
close this gap in order to achieve universal coverage. Furthermore, while availability of QAACT was generally high,
the implementation of the AL policy includes delivery of
four different AL pack sizes (6, 12, 18 and 24 tablets) suitable for management of four different weight categories of
patients. Availability of the different weight categories was
more variable among public health facilities, with less than
40% of outlets having the 18 tablet pack size in stock. Only
half of the public health facilities stocked treatment for
severe malaria, injectable artesunate, and this was similar
to levels in 2014 [18]. SP for IPTp was available in 70% of
public health facilities in endemic areas where it is recommended for IPTp, and rarely found among public health
facilities outside of the endemic areas, illustrating alignment with national guidelines in these areas.
Some of the gaps found among public health facilities
may be explained by changes in the supply and distribution
of anti-malarial medicines and RDTs in the public sector.
The Government of Kenya transitioned from a traditional
central medical store using a push-distribution system
to a pull-distribution system for malaria commodities,
through the Kenya Medical Supplies Agency (KEMSA).
However, the role of KEMSA to provide health commodities according to the requested needs (“pull” system) rather
than allocated proportions of the total supply (“push” system) presented a number of challenges [16], and resulted
in frequent stock-outs and erratic supplies of commodities to public health facilities. This has been attributed to
limited capacity to quantify needs, insufficient budget, and
challenges in maintaining a full pipeline of commodities
to meet county specific needs [5]. As a means to prevent
irrational anti-malarial medicines and RDT procurements
and stock-outs within the public sector, more recently the
National Malaria Control Programme and KEMSA have
implemented a “smart push” system for malaria commodities. This strategy sets limits on the maximum quantity
of malaria commodities that can be supplied to a facility, depending on the level of care and the epidemiological area. This strategy may help to further close the gap
in availability of both testing and treatment in the public
sector and will be important to safeguard the gains made
nationally in malaria case management.
The reach of the public sector has been extended to
the community-level through the training and equipping of CHW with malaria case management skills and
supplies in endemic areas since 2012 [3]. The findings
illustrate that a small portion of CHWs were ready for
malaria case management and these were restricted to
endemic and endemic-prone areas where interventions
are being piloted. Low levels of QAACT and RDT availability even within these areas may be explained by the
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lack of a consistent public sector malaria commodity
supply as previously discussed. Changes to the supply
and distribution of anti-malarial medicines in the public sector has been described as contributing to delays
in implementation of the malaria CHW strategy as public health facilities were either reluctant to give limited
malaria commodities to CHWs or had no commodities
to supply CHWs [5]. Maintaining a network of trained
and equipped CHWs will be central to ensuring access
to malaria case management services in rural areas. Key
challenges to be addressed include gaps in CHW motivation and retention, training and maintaining supervision [17].
The role of the private sector

Consistent with previous studies [18], the private sector plays an important role in malaria case management
given almost three-fourths of all anti-malarials were distributed through this sector. While unregistered pharmacies comprised most of the market share, other private
facilities also contributed to the anti-malarial distribution, including general retailers. As national policy stipulates that only private for-profit health facilities and
registered pharmacies are licensed to sell medications,
the results from this study suggest many anti-malarial
medicines are being distributed through unregulated
sources. Indeed, the Kenya Pharmacy and Poisons Board
stipulates that for outlets to legally administer medicines, including anti-malarials, they must be registered
with the board. In addition, medicines may only be dispensed under the supervision of a certified pharmacist
or pharmaceutical technologists [19]. However, given
the widespread distribution of anti-malarials through
unregistered pharmacies and general retailers, strategies
are needed to engage with these outlet types. One option
may be to permit the licensing of unregistered pharmacies through accreditation programmes, or through partnerships with the public sector, as a means to increase
access to appropriate malaria case management services.
Evidence from other countries has demonstrated that
the registration, training and supervision of the private
sector, can lend to improvements in malaria commodity
ACT availability, distribution and provider performance
[20–23].
Private sector readiness to test and treat for malaria

Among private sector outlets in the business of antimalarial distribution, fewer than half had QAACT available in 2016, reflecting a decrease from levels reported
in 2011 (60%) and 2014 (71%) [18]. Although the private
sector CPM for QAACT administered by the Global
Fund continued through 2016 in Kenya, important
changes and challenges in the post-pilot period are likely
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to have contributed to the decline in availability. Since
the AMFm, Kenya transitioned from a dedicated donor
funding to a country specific grant funding mechanism,
which was further amplified by a reduction in funding for co-paid ACTs. Indeed, the number of subsidized
QAACT doses delivered to Kenya’s private sector in 2015
through the CPM was half of what it was in 2012 [9].
In this context, lower availability of QAACT in the private sector as compared to previous rounds can largely
be explained by a more limited supply and availability of
these anti-malarials given reduced funding.
Only one in five private providers stocking anti-malarial medicines had confirmatory testing available and this
was highest among private for-profit facilities, reflecting national policy which only permits these types of
facilities to administer confirmatory testing. While the
private sector distributed the majority of anti-malarial
medicines, only one-third of malaria blood tests were
performed by private outlets, suggesting that presumptive treatment is common. Permitting other private sector outlet types to administer diagnostic testing may be
one means to increase access to confirmatory testing as
evidenced by a number of private sector RDT pilot initiatives [24–26]. Studies from Kenya have shown that registered pharmacies participating in a RDT pilot almost
always correctly managed negative patients as per the
government recommended treatment algorithm [11]. In
addition, there were few differences in the performance
of pharmacies and private for-profit health facilities,
lending to the author’s conclusion that malaria diagnosis
through RDTs can take place safely and effectively across
a variety of channels. Given the role of unregistered
pharmacies in Kenya, these facilities in particular may be
critical to increasing access to confirmatory testing prior
to treatment, though future research is merited to assess
the feasibility of introducing RDTs among these outlet
types. This is particularly pertinent as Kenya is deciding
whether to legalize and/or subsidize RDTs in registered
pharmacies as part of its malaria control strategy.
Market share

Most of the anti-malarial market share comprised of
QAACT, while one in four anti-malarials distributed were
SP—and most commonly distributed through the private
sector. Market share for QAACT was highest in endemic
areas as compared with other epidemiological areas
where distribution of SP was relatively common. In seasonal-transmission areas, SP accounted for nearly half of
all anti-malarial distribution with nearly all of these treatments going through the private sector. SP accounted for
about one-third of anti-malarials distributed in endemicprone and low-risk areas. This finding suggests that SP
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is being used for malaria case management within the
private sector and outside of endemic areas and points
to the need to ensure continued availability of affordable
QAACT in the private sector across the country, and not
just focused in endemic areas. Furthermore, these findings suggest that unless effective private sector strategies
are identified and implemented, further decline in private
sector availability may be observed. In absence of suboptimal private sector engagement and support, and social
and behaviour change communication for providers and
consumers to raise awareness of QAACT, Kenya may see
an increasing market share for SP.
Several reasons may explain the ongoing distribution
of SP for case management. This may be in part driven
by price as QAACT was approximately three times more
expensive than SP in the private sector. While the price
of SP has remained consistently low since 2010, the price
of QAACT has fluctuated, initially dropping to nearly the
same price as SP in 2011 but then increasing by 2014 [18].
The persistence of inexpensive SP may inhibit the uptake
of QAACT even with a subsidy mechanism in place, and
especially in the context of a reduced subsidy since the
AMFm period. Furthermore, in the absence of supportive interventions to increase awareness of subsidized
ACT (which ceased in 2015), providers and consumers
may have less awareness of the subsidized ACT medicine. Indeed, the results also illustrate how some private sector providers perceived non-ACT medicines as
the most effective treatment for uncomplicated malaria.
Finally, while availability of QAACT was low in the private sector, the data also illustrate how there was variability according to different pack sizes, perhaps causing
providers to ration ACTs. Other evidence has suggested
that providers will administer other artemisinin therapies
over ACT if supply is uncertain and availability is lower
than non-recommended treatments [27]. Additional
research to understand provider and consumer practices
and demand for SP will be valuable to provide insights
into the ongoing distribution.
Nearly one in five anti-malarials distributed were
non-QAACTs. Non-QAACT was about 2.5 times more
expensive than QAACT in the private sector. This raises
the question of why consumers would pay more for nonQAACT when less expensive QAACT are available?
Other ACTwatch research has shown that non-QAACT
products were primarily distributed by pharmacies and
drug stores in urban areas of Kenya. Thus the distribution
of non-QAACT may reflect a higher purchasing power of
urban consumers [28]. More research is needed to understand the reason for provider dispensing practices of
non-QAACT as well as consumer preferences. Addressing the availability and distribution of non-QAACT will

ACTwatch Group et al. Malar J (2017) 16:494

also require addressing elements of the supply chain, as
well a product registration, manufacturing, importation
laws and regulation.
Limitations

General limitations of the study design which are applicable to all ACTwatch outlet surveys have been described
in detail elsewhere [12, 14, 29]. In particular, the study is
descriptive in nature and the results are unable to provide
analytical information on the causal effects of interventions on the malaria testing and diagnostic landscape.

Conclusions
Although public sector readiness to test and appropriately treat malaria in Kenya is relatively high, there is a
gap in availability of both testing and treatment that must
be addressed in order to achieve universal coverage. Also
critical to achieving universal coverage with appropriate malaria case management in Kenya is the private sector, where the majority of anti-malarials are distributed.
This includes distribution of nearly half of all anti-malarial
medicines by unregistered and unregulated pharmacies
and general retail outlets. There is need for strategies to
effectively engage or regulate these outlet types. While private sector readiness to treat malaria according to national
guidelines improved with a large scale QAACT subsidy
piloted under the AMFm, availability of QAACT has subsequently declined to less than half of anti-malarial stocking private sector outlets in 2016. Given the continued role
of the private sector in anti-malarial distribution, there is
need for a renewed commitment and effective strategies to
ensure access to affordable QAACT in the private sector.
Additionally, given the aim of confirmatory testing prior to
treatment, the low availability of testing particularly among
the unregistered pharmacies, suggests need to examine
policies and strategies for private sector malaria testing.
Additional files
Additional file 1. Detailed sample description.
Additional file 2. Availability of QA AL, among all screened public sector
outlets.
Additional file 3. Availability of QAACT among anti-malarial stocking
outlets, by strata.
Additional file 4. Proportion of providers who report an ACT was the
most effective anti-malarial medicine for a child.
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